KR102585550B1 - 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물 - Google Patents

확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물 Download PDF

Info

Publication number
KR102585550B1
KR102585550B1 KR1020177022900A KR20177022900A KR102585550B1 KR 102585550 B1 KR102585550 B1 KR 102585550B1 KR 1020177022900 A KR1020177022900 A KR 1020177022900A KR 20177022900 A KR20177022900 A KR 20177022900A KR 102585550 B1 KR102585550 B1 KR 102585550B1
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
mmol
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177022900A
Other languages
English (en)
Korean (ko)
Other versions
KR20170113578A (ko
Inventor
조안 오슬롭
다니엘레 오벨레
재 킴
로버트 맥도웰
용홍 송
아빈더 스랜
민 종
Original Assignee
미요카디아, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미요카디아, 인크. filed Critical 미요카디아, 인크.
Priority to KR1020237033324A priority Critical patent/KR102688851B1/ko
Publication of KR20170113578A publication Critical patent/KR20170113578A/ko
Application granted granted Critical
Publication of KR102585550B1 publication Critical patent/KR102585550B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177022900A 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물 Active KR102585550B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237033324A KR102688851B1 (ko) 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562106571P 2015-01-22 2015-01-22
US62/106,571 2015-01-22
PCT/US2016/014365 WO2016118774A1 (en) 2015-01-22 2016-01-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237033324A Division KR102688851B1 (ko) 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물

Publications (2)

Publication Number Publication Date
KR20170113578A KR20170113578A (ko) 2017-10-12
KR102585550B1 true KR102585550B1 (ko) 2023-10-10

Family

ID=55275230

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247024828A Pending KR20240119163A (ko) 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물
KR1020177022900A Active KR102585550B1 (ko) 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물
KR1020237033324A Active KR102688851B1 (ko) 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020247024828A Pending KR20240119163A (ko) 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237033324A Active KR102688851B1 (ko) 2015-01-22 2016-01-21 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물

Country Status (36)

Country Link
US (1) US9925177B2 (enExample)
EP (2) EP4234017A3 (enExample)
JP (1) JP6712275B2 (enExample)
KR (3) KR20240119163A (enExample)
CN (3) CN111393414B (enExample)
AU (4) AU2016209200B2 (enExample)
BR (1) BR112017015627B1 (enExample)
CA (1) CA2974370C (enExample)
CL (1) CL2017001871A1 (enExample)
CO (1) CO2017008398A2 (enExample)
CR (1) CR20170370A (enExample)
DK (1) DK3247707T3 (enExample)
DO (2) DOP2017000166A (enExample)
EA (1) EA036923B1 (enExample)
EC (1) ECSP17054181A (enExample)
ES (1) ES2953480T3 (enExample)
FI (1) FI3247707T3 (enExample)
GT (1) GT201700163A (enExample)
HR (1) HRP20230737T1 (enExample)
HU (1) HUE063410T2 (enExample)
IL (6) IL313678A (enExample)
LT (1) LT3247707T (enExample)
MX (3) MX385960B (enExample)
MY (1) MY203427A (enExample)
PE (2) PE20171511A1 (enExample)
PH (2) PH12017501279B1 (enExample)
PL (1) PL3247707T3 (enExample)
PT (1) PT3247707T (enExample)
RS (1) RS64432B1 (enExample)
SG (2) SG11201705928XA (enExample)
SI (1) SI3247707T1 (enExample)
SM (1) SMT202300259T1 (enExample)
TN (1) TN2017000320A1 (enExample)
UA (1) UA119905C2 (enExample)
WO (1) WO2016118774A1 (enExample)
ZA (1) ZA201704777B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
WO2019055590A1 (en) 2017-09-13 2019-03-21 Amgen Inc. SARCOMERIC BISAMIDE ACTIVATOR COMPOUNDS AND USES THEREOF
SI3740481T1 (sl) 2018-01-19 2024-09-30 Cytokinetics, Inc. Analogi dihidrobenzofurana in indena kot zaviralci srčne sarkomere
EP3746434A4 (en) * 2018-02-01 2021-11-17 MyoKardia, Inc. PYRAZOLE COMPOUNDS AND THEIR PRODUCTION
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
GB201813312D0 (en) 2018-08-15 2018-09-26 Modern Biosciences Ltd Compounds and their therapeutic use
AU2019328556B2 (en) 2018-08-31 2025-09-04 Cytokinetics, Inc. Cardiac sarcomere inhibitors
GB201905520D0 (en) 2019-04-18 2019-06-05 Modern Biosciences Ltd Compounds and their therapeutic use
SG11202112723PA (en) * 2019-05-19 2021-12-30 Myokardia Inc Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
WO2021011586A1 (en) 2019-07-16 2021-01-21 MyoKardia, Inc. Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
KR20240131463A (ko) 2020-05-05 2024-08-30 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
EP4146626A4 (en) 2020-05-05 2024-05-29 Nuvalent, Inc. CHEMOTHERAPEUTIC AGENTS BASED ON HETEROAROMATIC MACROCYCLIC ETHERS
CA3180943A1 (en) * 2020-06-15 2021-12-23 Jean-Francois TAMBY Treatment of atrial dysfunction
KR102541297B1 (ko) 2020-08-18 2023-06-09 가톨릭대학교 산학협력단 확장성 심근병 모델 및 이의 제조방법
JP2024508526A (ja) 2021-03-04 2024-02-27 サイトキネティックス， インコーポレイテッド 心筋サルコメア阻害剤
KR20240087788A (ko) 2021-10-01 2024-06-19 뉴베일런트, 아이엔씨. 헤테로방향족 매크로사이클릭 에테르 화합물의 고체 형태, 약학 조성물 및 제조
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
WO2025244956A1 (en) 2024-05-20 2025-11-27 MyoKardia, Inc. Methods of manufacturing danicamtiv

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250789A1 (en) 2004-04-20 2005-11-10 Burns David M Hydroxamic acid derivatives as metalloprotease inhibitors
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552404A (en) * 2004-06-17 2010-04-30 Cytokinetics Inc Compounds, compositions and methods
US8324178B2 (en) 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
CA2778175A1 (en) * 2009-11-11 2011-05-19 Yoshihiro Horiuchi 8-azabicyclo[3.2.1]octane-8-carboxamide derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250789A1 (en) 2004-04-20 2005-11-10 Burns David M Hydroxamic acid derivatives as metalloprotease inhibitors
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds

Also Published As

Publication number Publication date
CN111393414B (zh) 2024-05-07
PT3247707T (pt) 2023-08-31
NZ734020A (en) 2023-11-24
CA2974370C (en) 2023-10-31
CN107428719B (zh) 2020-03-27
AU2020244490A1 (en) 2020-10-29
UA119905C2 (uk) 2019-08-27
CO2017008398A2 (es) 2017-10-31
EP3247707B1 (en) 2023-05-31
ZA201704777B (en) 2023-07-26
TN2017000320A1 (en) 2019-01-16
AU2020244490B2 (en) 2022-12-01
IL313678A (en) 2024-08-01
BR112017015627B1 (pt) 2022-11-16
PH12021553074A1 (en) 2023-03-06
MX2017009540A (es) 2017-10-20
AU2016209200B2 (en) 2020-07-02
US20160243100A1 (en) 2016-08-25
PH12017501279B1 (en) 2023-06-16
AU2016209200A1 (en) 2017-08-10
IL253552B (en) 2019-12-31
EP4234017A2 (en) 2023-08-30
IL271034A (en) 2020-01-30
HK1246775A1 (en) 2018-09-14
HUE063410T2 (hu) 2024-01-28
ES2953480T3 (es) 2023-11-13
KR20240119163A (ko) 2024-08-06
SG10201913047UA (en) 2020-02-27
DK3247707T3 (da) 2023-07-03
JP2018502883A (ja) 2018-02-01
MX394704B (es) 2025-03-24
IL279247A (en) 2021-01-31
DOP2017000166A (es) 2017-10-15
FI3247707T3 (fi) 2023-08-22
PE20171511A1 (es) 2017-10-20
MY203427A (en) 2024-06-27
SMT202300259T1 (it) 2023-09-06
CL2017001871A1 (es) 2018-04-13
PL3247707T3 (pl) 2023-12-11
MX2021010778A (es) 2022-08-11
PH12017501279A1 (en) 2018-01-29
AU2023200361A1 (en) 2023-02-23
WO2016118774A1 (en) 2016-07-28
MX2022007040A (es) 2022-06-24
RS64432B1 (sr) 2023-09-29
EP3247707A1 (en) 2017-11-29
CA2974370A1 (en) 2016-07-28
IL253552A0 (en) 2017-09-28
CN111393414A (zh) 2020-07-10
US9925177B2 (en) 2018-03-27
EA201791656A1 (ru) 2017-11-30
PE20212253A1 (es) 2021-11-24
MX385960B (es) 2025-03-18
KR20170113578A (ko) 2017-10-12
AU2024266781A1 (en) 2024-12-12
EA036923B1 (ru) 2021-01-15
HRP20230737T1 (hr) 2023-10-13
IL286369A (en) 2021-10-31
GT201700163A (es) 2018-10-18
CN118164961A (zh) 2024-06-11
CN107428719A (zh) 2017-12-01
EP4234017A3 (en) 2023-10-18
JP6712275B2 (ja) 2020-06-17
DOP2022000172A (es) 2022-09-30
SI3247707T1 (sl) 2023-10-30
KR20230145504A (ko) 2023-10-17
AU2023200361B2 (en) 2024-08-22
KR102688851B1 (ko) 2024-07-29
SG11201705928XA (en) 2017-08-30
CR20170370A (es) 2017-10-20
LT3247707T (lt) 2023-08-25
ECSP17054181A (es) 2019-02-28
IL295547A (en) 2022-10-01
BR112017015627A2 (pt) 2018-03-13

Similar Documents

Publication Publication Date Title
KR102585550B1 (ko) 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물
AU2019228568A1 (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
CA2838079A1 (en) Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
US20250275952A1 (en) 4-methylsulfonyl-substituted piperidine urea compounds
IL292416A (en) ssao inhibitors and their use
HK40100462A (en) 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
JPH11315020A (ja) 環状アミン誘導体を含有する医薬
HK40027481A (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
HK1246775B (en) 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
HK40027481B (zh) 用於治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物
NZ772098B2 (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601